Gilead Sciences, Inc business logo
Medicine Questions
Report an Adverse Event
Investors
Contact
Global Operations
North America
  • Canada
  • Mexico
  • USA
South America
  • Argentina
  • Brazil
Asia
  • China
  • Hong Kong
  • India
  • Japan
  • Korea
  • Singapore
  • Taiwan
Middle East
  • United Arab Emirates
  • Saudi Arabia
Africa
  • South Africa
Australia
  • Australia New Zealand
Europe
  • Austria
  • Belgium Luxembourg
  • Czech Republic & Slovakia
  • Denmark
  • Finland
  • France
  • Germany
  • Greece
  • Iceland
  • Ireland
  • Israel
  • Italy
  • Netherlands
  • Norway
  • Poland & The Baltics
  • Portugal
  • Russia
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Kingdom
Gilead Logo
  • Our Purpose
    Mission and Core Values Partnerships and Community Giving Sustainability Advancing Global Health Medication Access
  • About
    Leadership U.S. Locations How We Operate Ethics and Code of Conduct
  • Science & Medicine
    Medicines Pipeline Research Clinical Trials
  • News and Press
    Events Stories Newsroom Company Statements Annual Reports
  • Careers
    Inclusion and Diversity Now Hiring Culture Benefits Internships
  • Utility
    Privacy Statements Terms Of Use Social Media Guidelines EU Data Disclosure Sitemap
BACK TO MAIN MENU Partnerships and Community COMPASS Initiative HepConnect HIV Age Positively Lift RADIAN TRANScend
BACK TO MAIN MENU Giving What We Fund Funding Requests Gilead Foundation Gilead Public Health Award
BACK TO MAIN MENU Sustainability Our Business Is Sustainable Performance Reporting U.N. Global Compact U.N. Sustainable Development Goals
BACK TO MAIN MENU Advancing Global Health COVID-19 HCV Elimination
BACK TO MAIN MENU Medication Access U.S. Patient Access Disaster Product Replacement Global Access Authorized Distributors
BACK TO MAIN MENU How We Operate Governance Transparency
BACK TO MAIN MENU Ethics and Code of Conduct Policies Disclosures Anti-Counterfeiting Consumer Product Safety Supplier Information Anti-Bribery and Anti-Corruption Policy Political Contributions
BACK TO MAIN MENU Research Research Scholars Program Compassionate Use Investigator-Sponsored Research
BACK TO MAIN MENU Newsroom Press Releases Media Inquiries
BACK TO MAIN MENU Company Statements Gilead Sciences Response to Open Letter Regarding Access to AmBisome® (liposomal amphotericin B) Gilead Statement on New England Journal of Medicine Publication of Positive Phase 3 ASCENT Study of Trodelvy in Metastatic Triple-Negative Breast Cancer Gilead Sciences Statement on Phase 3 Veklury® (Remdesivir) Intravenous Study in High Risk Non-Hospitalized Patients with COVID-19 Gilead Announces Additional Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program Gilead Announces Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program Gilead Announces Plans for New Location in North Carolina’s Research Triangle Region Dedicated to Business Services Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD Gilead Sciences Statement on Recent Events in Washington, D.C. Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP® Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines
BACK TO MAIN MENU Annual Reports Year in Review 2020
BACK TO MAIN MENU Privacy Statements Cookie Statement
BACK TO MAIN MENU Social Media Guidelines Linkedin Guidelines Twitter Guidelines
BACK TO MAIN MENU
North America
  • Canada
  • Mexico
  • USA
South America
  • Argentina
  • Brazil
Asia
  • China
  • Hong Kong
  • India
  • Japan
  • Korea
  • Singapore
  • Taiwan
Middle East
  • United Arab Emirates
  • Saudi Arabia
Africa
  • South Africa
Australia
  • Australia New Zealand
Europe
  • Austria
  • Belgium Luxembourg
  • Czech Republic & Slovakia
  • Denmark
  • Finland
  • France
  • Germany
  • Greece
  • Iceland
  • Ireland
  • Israel
  • Italy
  • Netherlands
  • Norway
  • Poland & The Baltics
  • Portugal
  • Russia
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Kingdom
BACK TO MAIN MENU

Contact

  • Request Medicines Information
  • Report an Adverse Event
  • Information for Suppliers
  • Partnership Request
  • Medicine Questions
  • Report an Adverse Event
  • Investors
  • Contact
  • Global Operations
Toggle Inner Dropdown
BACK TO MAIN MENU Google.com
  • Mission and Core Values
  • Partnerships and Community
    • COMPASS Initiative
    • HepConnect
    • HIV Age Positively
    • Lift
    • RADIAN
    • TRANScend
  • Giving
    • What We Fund
    • Funding Requests
    • Gilead Foundation
    • Gilead Public Health Award
  • Sustainability
    • Our Business Is Sustainable
    • Performance
    • Reporting
    • U.N. Global Compact
    • U.N. Sustainable Development Goals
  • Advancing Global Health
    • COVID-19
    • HCV Elimination
  • Medication Access
    • U.S. Patient Access
    • Disaster Product Replacement
    • Global Access
    • Authorized Distributors

Gilead Foundation

The Gilead Foundation, a nonprofit organization established in 2005, seeks to improve the health and well-being of underserved communities around the world.  

The Gilead Foundation is not currently accepting proposals. 

To apply for financial support under Gilead’s Corporate Giving program, please visit the U.S. Corporate Grants and Giving  page.

Gilead Sciences, Inc business logo

© 1996-2021 Gilead Sciences, Inc. All rights reserved.

AREAS OF INTEREST

  • Partnerships and Community
  • Pipeline
  • Medicines
  • Job Search

INFORMATION

  • Contact Us
  • Report an Adverse Event
  • Press Room
  • Investor Calls
  • Sitemap

LEGAL

  • Privacy Policy
  • Terms of Use
  • EU Data Disclosure
  • Social Media Guidelines
  • Modern Slavery Act Statement

FOLLOW US

  • facebook
  • linkedin
  • twitter
  • youtube

Headline

Intersititial body copy

Ok Cancel

Welcome

Some content on this site is not intended for people outside the United States.


Accept